Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

P3 Health Partners (PIIIW) EBITDA (2020 - 2025)

Historic EBITDA for P3 Health Partners (PIIIW) over the last 6 years, with Q3 2025 value amounting to -$43.7 million.

  • P3 Health Partners' EBITDA rose 5890.31% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$252.5 million, marking a year-over-year decrease of 340.81%. This contributed to the annual value of -$318.3 million for FY2024, which is 9215.0% down from last year.
  • According to the latest figures from Q3 2025, P3 Health Partners' EBITDA is -$43.7 million, which was up 5890.31% from -$33.5 million recorded in Q2 2025.
  • P3 Health Partners' EBITDA's 5-year high stood at -$12.7 million during Q1 2021, with a 5-year trough of -$911.6 million in Q2 2022.
  • For the 5-year period, P3 Health Partners' EBITDA averaged around -$120.3 million, with its median value being -$43.7 million (2025).
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 341001.04% in 2022, then skyrocketed by 9775.85% in 2023.
  • P3 Health Partners' EBITDA (Quarter) stood at -$62.0 million in 2021, then tumbled by 764.78% to -$535.9 million in 2022, then soared by 88.1% to -$63.8 million in 2023, then tumbled by 116.13% to -$137.8 million in 2024, then skyrocketed by 68.27% to -$43.7 million in 2025.
  • Its EBITDA stands at -$43.7 million for Q3 2025, versus -$33.5 million for Q2 2025 and -$37.5 million for Q1 2025.